Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of Ruzotolimod in Healthy Chinese Volunteers
NCT03530917Phase 1Completed
- Sponsor
- Roche
- Start
- May 2018
- Primary completion
- May 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ruzotolimod in Chronic Hepatitis B (CHB) (8 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With Adverse Events. Started May 2018; status: completed.
02
Drugs
ruzotolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03530917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03530917.